Skip to main content
. 2020 Jan 25;12(2):145–154. doi: 10.1007/s12539-020-00358-8

Table 3.

MSI phenotypes grouped by the cancer development stage

Disease stage MSI-H MSI-L MSS Total
I 7 (53.8%) 2 (15.4%) 4 (30.8%) 13
II 19 (43.2%) 4 (9.1%) 21 (47.7%) 44
III 11 (29.7%) 1 (2.7%) 25 (67.6%) 37
IV 0 0 3 (100%) 3
Sum 37 7 53 97